Rheumatoid Arthritis

Immunology
319
Pipeline Programs
30
Companies
50
Clinical Trials
3 recruiting
20
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
49
4
103
4
100
59
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
7271%
Small Molecule
2929%
+ 303 programs with unclassified modality

On Market (20)

Approved therapies currently available

Roche
ACTEMRAApproved
tocilizumab
Roche
Interleukin-6 Receptor Antagonist [EPC]intravenous, subcutaneous2013
Sanofi
ARAVAApproved
leflunomide
Sanofi
Antirheumatic Agent [EPC]oral1998
U
AZASANApproved
azathioprine
Unknown Company
Purine Antimetabolite [EPC]oral1999
U
AZATHIOPRINEApproved
azathioprine
Unknown Company
Purine Antimetabolite [EPC]oral2020
U
BARICITINIBApproved
baricitinib
Unknown Company
oral2024
UP
CIMZIAApproved
certolizumab pegol
UCB Pharma
Tumor Necrosis Factor Blocker [EPC]injection2008
U
ENBRELApproved
etanercept
Unknown Company
Tumor Necrosis Factor Blocker [EPC]subcutaneous1998
AbbVie
HUMIRAApproved
adalimumab
AbbVie
2002
U
JYLAMVOApproved
methotrexate
Unknown Company
Folate Analog Metabolic Inhibitor [EPC]oral2022
Sanofi
KEVZARAApproved
sarilumab
Sanofi
Interleukin-6 Receptor Antagonist [EPC]injection2017
Swedish Orphan Biovitrum
KINERETApproved
anakinra
Swedish Orphan Biovitrum
Interleukin-1 Receptor Antagonist [EPC]subcutaneous2001
U
LEFLUNOMIDEApproved
leflunomide
Unknown Company
Antirheumatic Agent [EPC]oral2021
U
METHOTREXATE SODIUM PRESERVATIVE FREEApproved
methotrexate
Unknown Company
injection2010
Eli Lilly and Company
OLUMIANTApproved
baricitinib
Eli Lilly and Company
Janus Kinase Inhibitor [EPC]oral2018
Bristol Myers Squibb
ORENCIAApproved
abatacept
Bristol Myers Squibb
Selective T Cell Costimulation Modulator [EPC]iv (infusion)2005
U
OTREXUPApproved
methotrexate
Unknown Company
Folate Analog Metabolic Inhibitor [EPC]subcutaneous2013
U
OTREXUP PFSApproved
methotrexate
Unknown Company
Folate Analog Metabolic Inhibitor [EPC]subcutaneous2013
Astellas
PROGRAFApproved
tacrolimus
Astellas
oral1994
U
REMICADEApproved
infliximab
Unknown Company
Tumor Necrosis Factor Blocker [EPC]intravenous1998
Roche
RITUXANApproved
rituximab
Roche
CD20-directed Cytolytic Antibody [EPC]intravenous1997

Competitive Landscape

62 companies ranked by most advanced pipeline stage

UP
38 programs
2
5
18
7
Certolizumab PegolPhase 41 trial
Certolizumab PegolPhase 41 trial
Certolizumab pegolPhase 41 trial
Certolizumab pegolPhase 41 trial
CimziaPhase 41 trial
+33 more programs
Active Trials
NCT02804204Unknown200Est. Dec 2019
NCT03559686Available
NCT01764321Completed1,723Est. Jun 2020
+33 more trials
Pfizer
34 programs
3
3
1
2
Phase 1: EtanerceptPhase 4
UltrasonographyPhase 4
Prevenar 13Phase 31 trial
CP-690,550Phase 21 trial
PF-06650833Phase 23 trials
+29 more programs
Active Trials
NCT00794118Completed299Est. Apr 2011
NCT00793403Completed293Est. Jun 2010
NCT04515589Completed95Est. Sep 2023
+32 more trials
Bristol Myers Squibb
28 programs
6
1
1
1
AbataceptPhase 31 trial
AbataceptPhase 21 trial
AbataceptPhase 11 trial
BMS-582949 and MethotrexatePhase 11 trial
BMS-986195Phase 11 trial
+23 more programs
Active Trials
NCT04227535Active Not Recruiting509Est. Oct 2027
NCT01141413Completed5,451Est. Aug 2010
NCT01136694Completed695Est. Dec 2011
+24 more trials
Roche
RocheSTAVANGER NORWAY, Norway
28 programs
3
14
5
rituximabPhase 4Monoclonal Antibody1 trial
rituximab [MabThera/Rituxan]Phase 41 trial
tocilizumab [RoActemra/Actemra]Phase 41 trial
tocilizumab [RoActemra/Actemra]Phase 41 trial
tocilizumab [RoActemra/Actemra]Phase 41 trial
+23 more programs
Active Trials
NCT01071798Completed1,653Est. Oct 2014
NCT03109470Withdrawn0Est. Nov 2014
NCT00365001Completed23Est. Apr 2008
+32 more trials
Amgen
19 programs
1
2
5
1
4
AnakinraPhase 41 trial
EtanerceptPhase 45 trials
Phase 1: EtanerceptPhase 41 trial
SimpleJectTMPhase 41 trial
etanercept pre-filled syringe subcutaneous injectionPhase 31 trial
+14 more programs
Active Trials
NCT00439894Completed50Est. Oct 2007
NCT00117091Completed
NCT00116714Completed4,968Est. Oct 2008
+25 more trials
Abbott
18 programs
2
5
6
AdalimumabPhase 4Monoclonal Antibody1 trial
AdalimumabPhase 4Monoclonal Antibody1 trial
AdalimumabPhase 4Monoclonal Antibody1 trial
HumiraPhase 41 trial
UltrasonographyPhase 41 trial
+13 more programs
Active Trials
NCT01736189Completed346Est. Apr 2018
NCT01076959Completed7,972Est. Jun 2011
NCT01913080Completed67Est. Sep 2016
+15 more trials
AbbVie
16 programs
2
6
1
adalimumabPhase 4Monoclonal Antibody
ABT-122Phase 23 trials
AdalimumabPhase 2Monoclonal Antibody
Adalimumab delivered in current syringePhase 2
LutikizumabPhase 2Monoclonal Antibody1 trial
+11 more programs
Active Trials
NCT01768858Completed96Est. Aug 2017
NCT02668640Completed55Est. Aug 2018
NCT02322723Withdrawn0Est. Feb 2020
+13 more trials
Sanofi
15 programs
4
4
1
3
1
LeflunomidePhase 41 trial
SarilumabPhase 3Monoclonal Antibody1 trial
Sarilumab SAR153191Phase 31 trial
sarilumab SAR153191Phase 31 trial
SarilumabPhase 2/3Monoclonal Antibody5 trials
+10 more programs
Active Trials
NCT06714461Active Not Recruiting3,500Est. Mar 2026
NCT02101073Completed70Est. Jul 2014
NCT01328522Completed32Est. Sep 2011
+19 more trials
Galapagos
Galapagos2800 MECHELEN, Belgium
15 programs
2
8
3
2
FilgotinibPhase 4Small Molecule1 trial
FilgotinibPhase 4Small Molecule1 trial
FilgotinibPhase 3Small Molecule
FilgotinibPhase 3Small Molecule
FilgotinibPhase 3Small Molecule
+10 more programs
Active Trials
NCT01211249Completed30Est. Apr 2011
NCT01668641Completed91Est. Oct 2012
NCT01384422Completed36Est. Nov 2011
+5 more trials
E
13 programs
3
1
5
2
Filgotinib MaleatePhase 41 trial
MethotrexatePhase 41 trial
AdalimumabPhase 3Monoclonal Antibody
Double-blind adalimumabPhase 3Monoclonal Antibody
T-614Phase 31 trial
+8 more programs
Active Trials
NCT01850966Completed2,747Est. Apr 2014
NCT02960438Completed273Est. Sep 2019
NCT02960490Completed66Est. Nov 2019
+3 more trials
Regeneron
RegeneronTARRYTOWN, NY
11 programs
3
1
6
1
SARILUMABPhase 4Monoclonal Antibody
SarilumabPhase 3Monoclonal Antibody
SarilumabPhase 3Monoclonal Antibody
SarilumabPhase 3Monoclonal Antibody1 trial
Sarilumab SAR153191Phase 3
+6 more programs
Active Trials
NCT07154290Not Yet Recruiting300Est. Jun 2030
Genentech
9 programs
4
3
2
TocilizumabPhase 4Monoclonal Antibody1 trial
tocilizumabPhase 4Monoclonal Antibody1 trial
MethotrexatePhase 31 trial
MethotrexatePhase 31 trial
folatePhase 3
+4 more programs
Active Trials
NCT01225393Completed211
NCT00282308Completed103Est. May 2012
NCT00147966Completed24Est. Dec 2009
+4 more trials
Astellas
AstellasChina - Shenyang
7 programs
1
3
1
TacrolimusPhase 41 trial
Certolizumab pegolPhase 3
PeficitinibPhase 3Small Molecule1 trial
TacrolimusPhase 31 trial
peficitinibPhase 1Small Molecule1 trial
+2 more programs
Active Trials
NCT01339481Completed26Est. Oct 2011
NCT01870908Completed664Est. Mar 2015
NCT01754805Completed15Est. Mar 2010
+3 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
7 programs
1
2
3
1
BaricitinibPhase 4Small Molecule1 trial
LY2127399Phase 31 trial
LY2127399Phase 35 trials
baricitinib treatmentPhase 31 trial
LY2127399Phase 21 trial
+2 more programs
Active Trials
NCT01236118Completed28Est. Jan 2013
NCT01576549Terminated2Est. May 2013
NCT05848258Recruiting380Est. Jul 2026
+8 more trials
Swedish Orphan Biovitrum
2
2
AnakinraPhase 4
SimpleJectTMPhase 4
anakinraPhase 2
anakinraPhase 2
AnakinraN/A1 trial
Active Trials
NCT02915094CompletedEst. Jan 2016
M&
Merck & Co.RAHWAY, NJ
4 programs
1
1
MK0966; rofecoxibPhase 4Small Molecule1 trial
MK-8808Phase 11 trial
Differences in Bone Cell Activity Between Rheumatoid Arthritis and Ankylosing SpondylitisN/A1 trial
OriginatorN/A1 trial
Active Trials
NCT01417455Completed101Est. May 2015
NCT03470688Unknown5,000Est. Dec 2021
NCT01390441Terminated100Est. Apr 2014
+1 more trials
Verona Pharma
1 program
1
FilgotinibPhase 4Small Molecule1 trial
Active Trials
NCT06527534Recruiting30Est. Sep 2025
GS
Gilead SciencesFOSTER CITY, CA
15 programs
5
5
3
FilgotinibPhase 3Small Molecule1 trial
FilgotinibPhase 3Small Molecule
FilgotinibPhase 3Small Molecule1 trial
AndecaliximabPhase 2Monoclonal Antibody1 trial
FilgotinibPhase 2Small Molecule1 trial
+10 more programs
Active Trials
NCT04226131Completed21Est. Jul 2023
NCT00499187Completed56Est. Mar 2011
NCT04608344Completed27Est. Jan 2021
+9 more trials
Biogen
14 programs
1
8
3
RituximabPhase 3Monoclonal Antibody1 trial
baricitinib treatmentPhase 3
methotrexatePhase 34 trials
BG00012Phase 21 trial
BG9924Phase 21 trial
+9 more programs
Active Trials
NCT03100734Completed585Est. Nov 2018
NCT03327454Completed500Est. Jun 2018
NCT00771329Completed53Est. Apr 2011
+13 more trials
Celltrion
CelltrionKorea - Incheon
12 programs
1
9
CT-P10Phase 31 trial
CT-P13Phase 31 trial
CT-P13Phase 31 trial
CT-P17 SCPhase 31 trial
CT-P17 SC AIPhase 31 trial
+7 more programs
Active Trials
NCT05427942Unknown300Est. Mar 2023
NCT05866614Recruiting864Est. Mar 2027
NCT01534884Completed154Est. Feb 2014
+9 more trials
CP
11 programs
1
7
MRAPhase 31 trial
MRAPhase 31 trial
MRAPhase 31 trial
MRAPhase 31 trial
MRAPhase 31 trial
+6 more programs
Active Trials
NCT01315652Completed970Est. Jan 2016
NCT00144573Completed14Est. Oct 2005
NCT00144560Completed31Est. Aug 2005
+8 more trials
DS
6 programs
3
2
CHS-0214Phase 3
EtanerceptPhase 3
AC430Phase 11 trial
AMP-110Phase 11 trial
AMP-110Phase 11 trial
+1 more programs
Active Trials
NCT01973569Completed679Est. Sep 2017
NCT01287858Completed88Est. Jun 2011
NCT01878123Completed26Est. Jul 2014
+1 more trials
SetPoint Medical
SetPoint MedicalCA - Valencia
5 programs
1
1
Implant ProcedurePhase 31 trial
Cyberonics VNS SystemPhase 1/21 trial
Cyberonics VNS SystemN/A1 trial
SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway SystemN/A1 trial
SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway SystemN/A1 trial
Active Trials
NCT01552941Completed18Est. May 2014
NCT04862117Active Not Recruiting14Est. Dec 2026
NCT03437473Completed14Est. Dec 2018
+2 more trials
Fresenius Kabi
Fresenius KabiGermany - Bad Homburg
4 programs
1
1
MSB11456Phase 31 trial
40 mg MSB11022Phase 11 trial
Real World Use of Tocilizumab Biosimilar studYN/A1 trial
bIosimilar of aDalimumab, an European evAluationN/A1 trial
Active Trials
NCT06247722Active Not Recruiting600Est. Mar 2026
NCT05190484Unknown1,050Est. Apr 2024
NCT04018599Completed216Est. Mar 2020
+1 more trials
Sandoz
4 programs
2
2
Adalimumab - GP2017Phase 31 trial
GP2013 - A Proposed biosimilar rituximabPhase 3Monoclonal Antibody1 trial
Leflunomide 20 mg TabletsPhase 11 trial
Naproxen Delayed Release Tables, 375Phase 11 trial
Active Trials
NCT00946686CompletedEst. Sep 2002
NCT00959439CompletedEst. May 2002
NCT02744755CompletedEst. Sep 2017
+1 more trials
Coherus Oncology
2
CHS-0214Phase 31 trial
EtanerceptPhase 31 trial
Active Trials
NCT02486939Completed359Est. Oct 2017
NCT02115750Completed647Est. May 2016
Mabion
MabionPoland - Konstantynów
2 programs
2
MabionCD20Phase 31 trial
RituximabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT04680962Withdrawn0Est. Aug 2023
NCT02468791Completed709Est. Oct 2017
Alvotech
1 program
1
AVT05Phase 31 trial
Active Trials
NCT05842213Completed502Est. Sep 2024
FUJIFILM Pharma
FUJIFILM PharmaMA - Cambridge
1 program
1
T-614Phase 3
VP
4
1
VX-509Phase 2/31 trial
VX-509Phase 21 trial
VX-509Phase 21 trial
VX-702Phase 21 trial
VX-702Phase 21 trial
Active Trials
NCT01590459Completed359Est. Jul 2014
NCT01754935Completed43Est. Feb 2014
NCT00395577Completed120Est. Jul 2007
+2 more trials

+32 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
AmgenAnakinra
SanofiSarilumab
EisaiFilgotinib Maleate
Verona PharmaFilgotinib
AbbVieUpadacitinib
GalapagosFilgotinib
AmgenEtanercept
GalapagosFilgotinib
Eli Lilly and CompanyBaricitinib
AmgenEtanercept
RocheTocilizumab
EisaiMethotrexate
SanofiSarilumab
Genentechtocilizumab
RocheTocilizumab

Showing 15 of 49 trials with date data

Clinical Trials (50)

Total enrollment: 11,102 patients across 50 trials

Evaluating the Effect of Anakinra (r-metHuIL-1ra) on Vaccine AntibodyResponse in Subjects With Rheumatoid Arthritis (RA)

Est. completion: Nov 2003
Phase 4Completed
NCT00121043AmgenSimpleJectTM

Evaluating Kineret® (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using aSelf-Reported Questionnaire

Phase 4Completed

Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica

Start: Apr 2026Est. completion: Jul 2029300 patients
Phase 4Not Yet Recruiting
NCT06625242EisaiFilgotinib Maleate

A Study of Filgotinib in Korean Participants With Rheumatoid Arthritis

Start: Oct 2024Est. completion: Mar 2026118 patients
Phase 4Active Not Recruiting

Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)

Start: Jul 2024Est. completion: Sep 202530 patients
Phase 4Recruiting
NCT06773403AbbVieUpadacitinib

Upadacitinib for Prurigo Nodularis

Start: Apr 2024Est. completion: Jan 202625 patients
Phase 4Recruiting

Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid Arthritis

Start: Oct 2022Est. completion: Oct 202540 patients
Phase 4Unknown

Etanercept Therapy for Nails Psoriasis Monitoring With Noninvasive Imaging

Start: Aug 2021Est. completion: Aug 202210 patients
Phase 4Unknown

Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH)

Start: May 2021Est. completion: Sep 2025100 patients
Phase 4Recruiting

A Study of Baricitinib in Participants With Rheumatoid Arthritis

Start: Feb 2020Est. completion: May 20251,317 patients
Phase 4Completed

Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout

Start: Oct 2019Est. completion: Aug 20215 patients
Phase 4Terminated
NCT03301883RocheTocilizumab

A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)

Start: Apr 2018Est. completion: Aug 202262 patients
Phase 4Completed
NCT03505008EisaiMethotrexate

Evaluation of the Optimal MTX Dose as an Add-on Therapy to Adalimumab for RA Patients in Japan, South Korea and Taiwan

Start: Apr 2018Est. completion: May 2021300 patients
Phase 4Completed

Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis

Start: Mar 2018Est. completion: Jul 201984 patients
Phase 4Completed

Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis

Start: May 2016Est. completion: Nov 201916 patients
Phase 4Terminated
NCT02682823RocheTocilizumab

Tocilizumab Real-Life Human Factors (RLHFs) Validation Study

Start: Mar 2016Est. completion: Jul 201691 patients
Phase 4Completed

IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

Start: Aug 2015Est. completion: Dec 201732 patients
Phase 4Completed

Evaluate Effects of Personalized Patient Counselling for Enbrel® Therapy in Adults With Rheumatoid Arthritis

Start: Apr 2015Est. completion: Oct 201519 patients
Phase 4Terminated

Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis

Start: Jan 2015Est. completion: Nov 2015132 patients
Phase 4Completed

Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab

Start: Sep 2014Est. completion: Apr 201774 patients
Phase 4Completed

Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept

Start: Jun 2013Est. completion: Mar 2014217 patients
Phase 4Completed

Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab

Start: May 2013Est. completion: Jun 201590 patients
Phase 4Terminated
NCT04157010RocheTocilizumab

Tocilizumab REMission in Early RA

Start: May 2013Est. completion: Mar 201620 patients
Phase 4Completed

Doppler Evaluation in RA Patients After Adalimumab.

Start: Oct 2012Est. completion: Sep 201760 patients
Phase 4Completed
NCT01661140RocheTocilizumab

A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage

Start: Sep 2012Est. completion: Feb 2015427 patients
Phase 4Terminated

Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab

Start: Feb 2012Est. completion: May 201564 patients
Phase 4Terminated

A Study is to Assess Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Who Showed Unsuccessful Response to Existing Disease Modifying Antirheumatic Drugs (DMARDs)

Start: Dec 2011Est. completion: May 2015128 patients
Phase 4Completed
NCT01500278UCB PharmaCertolizumab Pegol

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Start: Dec 2011Est. completion: Jan 2016915 patients
Phase 4Completed
NCT01443364UCB PharmaCertolizumab pegol

Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis

Start: Dec 2011Est. completion: May 2015132 patients
Phase 4Completed
NCT01251120RocheTocilizumab

A Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid Arthritis

Start: Nov 2011Est. completion: Jan 20132 patients
Phase 4Terminated
NCT01331837RocheTocilizumab

A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors

Start: Aug 2011Est. completion: Mar 20163,080 patients
Phase 4Completed
NCT01283971Rochetocilizumab [RoActemra/Actemra]

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor

Start: May 2011Est. completion: Aug 201296 patients
Phase 4Terminated
NCT01255761UCB PharmaCertolizumab Pegol

A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects

Start: Nov 2010Est. completion: Dec 2012736 patients
Phase 4Completed
NCT01149057RocheTocilizumab

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS

Start: Oct 2010Est. completion: Jul 2014145 patients
Phase 4Completed

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Start: Sep 2010Est. completion: Jan 2013309 patients
Phase 4Completed
NCT01205854AbbottUltrasonography

Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial

Start: Sep 2010Est. completion: Apr 2015238 patients
Phase 4Completed

Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia

Start: Jul 2010Est. completion: Jan 201237 patients
Phase 4Completed

An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use

Start: Apr 2010Est. completion: Dec 201020 patients
Phase 4Unknown
NCT01034397Rochetocilizumab [RoActemra/Actemra]

A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs

Start: Mar 2010Est. completion: Sep 201154 patients
Phase 4Completed
NCT02010216RocheTocilizumab

A Study of RoActemra/Actemra (Tocilizumab) in Adult Patients With Rheumatoid Arthritis (SVOBODA Programme)

Start: Mar 2010Est. completion: Jul 201023 patients
Phase 4Completed
NCT01089023Rochetocilizumab [RoActemra/Actemra]

A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis

Start: Jan 2010Est. completion: Dec 201195 patients
Phase 4Completed

Human Tumor Necrosis Factor Alpha (TNFa)-Induced Pre-B Cell Bone Marrow Emigrants

Start: Nov 2009Est. completion: Feb 20120
Phase 4Withdrawn
NCT00996203RocheTocilizumab

A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs.

Start: Oct 2009Est. completion: Feb 2011201 patients
Phase 4Completed

Safety and Efficacy of Etanercept in Patients With Psoriasis Who Failed to Respond to Other Biologic Treatments

Start: Sep 2009Est. completion: Jul 201489 patients
Phase 4Completed
NCT01010503RocheTocilizumab

A Study of Tocilizumab With or Without Methotrexate in Patients With Rheumatoid Arthritis.

Start: Jun 2009Est. completion: May 201032 patients
Phase 4Completed
NCT00848354AmgenPhase 1: Etanercept

Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy

Start: Jun 2009Est. completion: Apr 2013429 patients
Phase 4Completed

CAMEO: Canadian Methotrexate and Etanercept Outcome Study

Start: Jun 2008Est. completion: Feb 2013258 patients
Phase 4Completed

Safety and Efficacy of Combining nbUVB to Etanercept in Patients

Start: Apr 2008Est. completion: Mar 201099 patients
Phase 4Completed
NCT01000610Rocherituximab [MabThera/Rituxan]

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Start: Mar 2008Est. completion: May 201218 patients
Phase 4Completed
NCT00580840UCB PharmaCertolizumab pegol

Dosing Flexibility Study in Patients With Rheumatoid Arthritis

Start: Dec 2007Est. completion: Mar 2011333 patients
Phase 4Completed

Related Jobs in Immunology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

100 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 11,102 patients
30 companies competing in this space